Premium
The pharmacokinetics of xamoterol in liver disease.
Author(s) -
Nicholls DP,
Taggart AJ,
McCann JP,
Bastain W,
Shanks RG
Publication year - 1989
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/j.1365-2125.1989.tb03566.x
Subject(s) - pharmacokinetics , bioavailability , partial agonist , oral administration , medicine , disposition , agonist , heart failure , liver disease , endocrinology , chemistry , pharmacology , receptor , psychology , social psychology
The pharmacokinetics of xamoterol, a beta 1‐adrenoceptor partial agonist, have been studied in patients with liver disease and a group of age‐ and sex‐matched normal controls. No significant differences were observed after the oral administration of xamoterol 200 mg. The low bioavailability of xamoterol was confirmed (6.1% in patients, 6.9% in controls). After i.v. xamoterol 0.2 mg kg‐1, no significant differences between the groups were observed. A small increase in the terminal plasma elimination half‐life (t1/2) was observed in patients when compared with controls (15.3 +/‐ 6.4 vs 8.4 +/‐ 2.8 h, mean +/‐ s.d., P = 0.08). Renal clearance accounted for about 50% of total clearance in patients and about 30% in controls. It is suggested that in patients with heart failure, hepatic dysfunction would probably not influence xamoterol disposition.